1. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
- Author
-
Kavitha Saravu, Hemant K. Mishra, Nitin Gupta, Natalie L. Reierson, Adam A Dmytriw, Kirk W. Evanson, Sriram Varsha, Betsy Joseph, Kevin M. Kallmes, Praneeth Reddy Keesari, Yashwitha Sai Pulakurthi, Charan Thej Reddy Vegivinti, Geeta Paranjape, Jillienne C. Touchette, Spandana Chittajallu, Shelby Kamrowski, Amber R. Davis, Nick Mikoff, Pragadeesh Thamarai Selvan, Mahmoud Dibas, Megan Schmidt, and John M. Pederson
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Lopinavir/ritonavir ,Disease ,Antiviral Agents ,Microbiology ,Lopinavir ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Virology ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Ritonavir ,SARS-CoV-2 ,business.industry ,COVID-19 Drug Treatment ,Drug Combinations ,Treatment Outcome ,Infectious Diseases ,Observational study ,business ,medicine.drug - Abstract
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19. Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studies, single-armed studies, not written in English, not relevant to the topic, or published before May 2020. The included outcomes were viral clearance as measured by reverse-transcription polymerase chain reaction (RT-PCR) negativity and/or improvement on chest computed tomography (CT), mortality, and adverse events. Results: Among 858 total studies, 16 studies met the inclusion criteria and were included in the qualitative review. These studies consisted of 3 randomized control trials, 3 open-label trials, and 10 observational studies. Most of these studies did not report positive clinical outcomes with LPV/r treatment. Conclusion: The systematic review revealed insufficient evidence of effectiveness and clinical benefit of LPV/r in the treatment of COVID-19 patients. Specifically, LPV/r does not appear to improve clinical outcome, mortality, time to RT-PCR negativity, or chest CT clearance in patients with COVID-19.
- Published
- 2020
- Full Text
- View/download PDF